Episode
Rewriting Drug Discovery with an AI-Multi-Omics Approach
- Podcast
- The Bio Report
- Published
- Nov 26, 2025
- Duration seconds
- 2749
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/rewriting-drug-discovery-with-an-ai-multi-omics-approach/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/rewriting-drug-discovery-with-an-ai-multi-omics-approach.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
The genomics revolution promised to unravel diseases and lead to treatments that addressed their root causes. In reality, says Mo Jain, your zip code remains a better predictor for how healthy you will be over the course of your life than your genetic code does. That’s because, except for monogenic diseases, etiology tends to be far more complex than the identification of a single gene. Sapient is using its AI-driven, multi-omics platform to advance the discovery and development of precision medicines. We spoke to Jain, chief scientific officer of Sapient, about how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.